Nanna Lüneborg PhD, MBA
General Partner
The company’s platform identifies neural circuits causally linked to disease and targets those circuits with novel therapeutics.
MapLight’s lead candidate, ML-007C-MA, is an oral fixed-dose combination of a CNS-penetrant M1/M4 muscarinic agonist (ML-007) with a peripherally acting anticholinergic. This combination is designed to drive efficacy through dual M1/M4 activation in the brain while minimising peripheral side effects by aligning the pharmacokinetics of its components.
Industry
Biotech
Status
Current
Maplight is pioneering innovative new therapies for patients suffering from brain disorders. Forbion has been a great partner to us in catalyzing one of the largest private financing rounds in 2025, together with an outstanding syndicate of private, public and strategic investors. This financing provides critical support for two significant Phase 2 studies of our lead molecule, ML-007, while continuing to advance the rest of MapLight's pipeline. We look forward to continuing our partnership with Forbion and our other shareholders to bring important medicines to patients with central nervous system disorders.Chris Kroeger
CEO of MapLight Therapeutics
$372.5m
Series D Oversubscribed
Forbion team
Regina Salvat PhD
Principal